Dengue, caused by the four serotypes of dengue virus (DENV), represents an expanding global health challenge. The potential for serotype-cross-reactive antibodies to exacerbate disease during a secondary infection with a heterologous DENV serotype has driven efforts to study human DENV-specific antibodies. Most DENV-specific antibodies generated in humans are serotype-cross-reactive, weakly neutralizing, and directed against the immature pre-membrane (prM), envelope (E), and nonstructural 1 (NS1) proteins. To broaden the characterization of human DENV-specific antibodies, we assessed B-cell responses by ELISpot assays and isolated B cells from the peripheral blood of a human subject with previous DENV infection. Forty-eight human IgG monoclonal antibodies (hMAbs) were initially characterized by their potential to bind to an inactivated lysate of DENV-infected cells. Subsequently, most DENV-specific hMAbs were found to bind soluble, recombinant E protein (rE). Two hMAbs were unable to bind rE, despite strongly binding to the DENV-infected cell lysate. Further analyses showed that these two hMAbs bound conformation-dependent, reduction-sensitive epitopes on E protein. These data shed light on the breadth of DENV-specific hMAbs generated within a single immune donor.
Get full access to this article
View all access options for this article.
References
1.
BeltramelloM, WilliamsKL, SimmonsCPet al.The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe, 2010; 8:271–283.
2.
CavaciniL, PosnerM. Native HIV type 1 virion surface structures: relationships between antibody binding and neutralization or lessons from the viral capture assay. AIDS Res Hum Retroviruses, 2004; 20:435–441.
3.
ClementsDE, CollerBA, LiebermanMMet al.Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine, 2010; 28:2705–2715.
CrillWD, RoehrigJT. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol, 2001; 75:7769–7773.
6.
de AlwisR, BeltramelloM, MesserWBet al.In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis, 2010; 5:e1188.
7.
de AlwisR, SmithSA, OlivarezNPet al.Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci USA, 2012.
DowdKA, PiersonTC. Antibody-mediated neutralization of flaviviruses: a reductionist view. Virology, 2011; 411:306–315.
10.
FalconarAK. Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins. Arch Virol, 1999; 144:2313–2330.
11.
FalconarAK, YoungPR. Production of dimer-specific and dengue virus group cross-reactive mouse monoclonal antibodies to the dengue 2 virus non-structural glycoprotein NS1. J Gen Virol, 1991; 72,Pt 4:961–965.
12.
FalconarAK, YoungPR, MilesMA. Precise location of sequential dengue virus subcomplex and complex B cell epitopes on the nonstructural-1 glycoprotein. Arch Virol, 1994; 137:315–326.
13.
GagnonSJ, ZengW, KuraneI, EnnisFA. Identification of two epitopes on the dengue 4 virus capsid protein recognized by a serotype-specific and a panel of serotype-cross-reactive human CD4+ cytotoxic T-lymphocyte clones. J Virol, 1996; 70:141–147.
14.
GuzmanMG, AlvarezM, Rodriguez-RocheRet al.Neutralizing antibodies after infection with dengue 1 virus. Emerg Infect Dis, 2007; 13:282–286.
15.
HennAD, RebhahnJ, BrownMAet al.Modulation of single-cell IgG secretion frequency and rates in human memory B cells by CpG DNA, CD40L, IL-21, and cell division. J Immunol, 2009; 183:3177–3187.
16.
HugginsJ, PellegrinT, FelgarREet al.CpG DNA activation and plasma-cell differentiation of CD27-naive human B cells. Blood, 2007; 109:1611–1619.
17.
JacksonSM, WilsonPC, JamesJA, CapraJD. Human B cell subsets. Adv Immunol, 2008; 98:151–224.
18.
LaiCY, TsaiWY, LinSRet al.Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol, 2008; 82:6631–6643.
19.
MathewA, WestK, KalayanaroojSet al.B-cell responses during primary and secondary dengue virus infections in humans. J Infect Dis, 2011; 204:1514–1522.
20.
ModisY, OgataS, ClementsD, HarrisonSC. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci USA, 2003; 100:6986–6991.
21.
MurphyBR, WhiteheadSS. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol, 2011; 29:587–619.
22.
O'NionsJ, AlldayMJ. Proliferation and differentiation in isogenic populations of peripheral B cells activated by Epstein-Barr virus or T cell-derived mitogens. J Gen Virol, 2004; 85:881–895.
23.
OliphantT, NybakkenGE, EngleMet al.Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol, 2006; 80:12149–12159.
24.
Perez-AndresM, PaivaB, NietoWGet al.Human peripheral blood B-cell compartments: a crossroad in B-cell traffic. Cytometry B Clin Cytom, 2010; 78,Suppl 1:S47–S60.
25.
RobinsonJE, HoltonD, LiuJ, McMurdoH, MurcianoA, GohdR. A novel enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies to HIV-1 envelope glycoproteins based on immobilization of viral glycoproteins in microtiter wells coated with concanavalin A. J Immunol Methods, 1990; 132:63–71.
26.
Rodenhuis-ZybertIA, van der SchaarHM, da Silva VoorhamJMet al.Immature dengue virus: a veiled pathogen?PLoS Pathog, 2010; 6:e1000718.
27.
RoehrigJT, BolinRA, KellyRG. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology, 1998; 246:317–328.
28.
RothmanAL. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol, 2011; 11:532–543.
29.
SchieffelinJS, CostinJM, NicholsonCOet al.Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient. Virol J, 2010; 7:28.
30.
ShresthaB, BrienJD, Sukupolvi-PettySet al.The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog, 2010; 6:e1000823.
31.
SimmonsCP, ChauTN, ThuyTTet al.Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J Infect Dis, 2007; 196:416–424.
32.
SmithSA, ZhouY, OlivarezNP, BroadwaterAH, de SilvaAM, CroweJEJr. Persistence of circulating B memory cell clones with potential for dengue virus disease enhancement for decades following infection. J Virol, 2011, 10.1128/JVI.06335-11.
33.
Sukupolvi-PettyS, AustinSK, EngleMet al.Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol, 2010; 84:9227–9239.
34.
Sukupolvi-PettyS, AustinSK, PurthaWEet al.Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol, 2007; 81:12816–12826.
35.
TangyeSG, TarlintonDM. Memory B cells: effectors of long-lived immune responses. Eur J Immunol, 2009; 39:2065–2075.
36.
TraggiaiE, BeckerS, SubbaraoKet al.An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med, 2004; 10:871–875.
37.
TraggiaiE, ChichaL, MazzucchelliLet al.Development of a human adaptive immune system in cord blood cell-transplanted mice. Science, 2004; 304:104–107.
38.
UngchusakK, KunasolP. Dengue haemorrhagic fever in Thailand, 1987. Southeast Asian J Trop Med Public Health, 1988; 19:487–490.
39.
ValdesK, AlvarezM, PupoM, VazquezS, RodriguezR, GuzmanMG. Human Dengue antibodies against structural and nonstructural proteins. Clin Diagn Lab Immunol, 2000; 7:856–857.
40.
WahalaWM, KrausAA, HaymoreLB, Accavitti-LoperMA, de SilvaAM. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology, 2009; 392:103–113.
41.
WrammertJ, SmithK, MillerJet al.Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature, 2008; 453:667–671.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
